Subscribe to Updates in Legal, Economic & Regulatory Affairs

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Biotechnology Patent Experts: Lawyers (US)

Articles with lock require a subscription to GLG News | Request a free trial
Patrick Joseph IgoeApril 9, 2007
The NORVASC® Battles Continue (Even After Federal Circuit Opinion)
Analysis of: Federal Circuit Opinion: Pfizer v Apotex | www.fedcir.gov
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
The March 22, 2007 CAFC Opinion invalidates claims 1-3 of US Patent 4879303, which is listed in the FDA Orange Book for Pfizer's blockbuster blood pressure drug NORVASC® (amylodipine besylate).  For companies other than Pfizer, this is great news - but it is not the end of the...
April 3, 2007
Voda v. Cordis: Patent Holder Cannot Assert Foreign Patents in U.S. Court
Analysis of: Voda v. Cordis Corporation | www.fedcirc.us
Author: GLG Expert Contributor
Patent holders may not be able to sue in one U.S. court for infringing both U.S. and foreign patents.  This could make enforcement of patents significantly more expensive and complex.
Patrick Joseph IgoeApril 2, 2007
Court Limits Piecemeal Infringement Assertions By Innovator Rx Company Against Generic Rx Company
Analysis of: Teva v Novartis: Federal Circuit Opinion | fedcir.gov
Author: Patrick Joseph Igoe, Life Sciences Patent Attorney, Independent IP Litigation Consultant
From among 5 patents listed in the FDA Orange Book, Novartis sued Teva for patent infringement of only 1 patent.  Teva filed a corresponding declaratory judgement action against Novartis seeking adjudication of the remaining 4 patents.  In its recent ruling, the Federal Circuit agrees...
Thomas SaundersMarch 1, 2007
Defending Knock-Offs: Head-to-head With Brand Names in Trademark, Copyright, and Internet Marketing
Analysis of: Defending Knock-Offs: Head-to-head With Brand Names in Trademark, Copyright, and Internet Marketing | www.iptoday.com
Author: Thomas Saunders, Of Counsel, Seyfarth Shaw LLP
-Name Brands vs, Knock-Offs: Strategies and Counter-Strategies -Vulnerabilities of Name Brand Copyrights -Why the internet Knock-Off market will always exist

Previous Page : 1 211 to 14 of 14

More GLG News in
Legal, Economic & Regulatory Affairs

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T13:45:22.747